China Sinopharm International (Shanghai) Co., Ltd.  

Product Name: Acetylsalicylic Acid CAS 50-78-2 Standard: USP Trademark: XINHUA Transport Package: 25kg/Drum Specification: 25kg Origin: China Product Description Acetylsalicylic acid, also known as aspirin, is an analgesic-antipyretic medicine made by salicylic acid interacting with acetic anhydride. It is a white crystalline powder, odorless, stable in dry air. It will be slowly hydrolyzed to be salicylic acid and acetic acid in moist air, and aqueous solution has acidic reaction. Slightly soluble in water, soluble in ethanol, ethyl ether, chloroform, sodium hydroxide solution and sodium carbonate solution. Acetylsalicylic acid has antipyretic analgesic, anti-inflammatory and anti-rheumatism effect, that's why it is often used for fever, headache, muscle pain, neuralgia, rheumatic fever, acute rheumatic arthritis, gout, etc.; also it has antiplatelet aggregation effect, and can be used for prevention of arterial thrombosis, atherosclerosis, transient cerebral ischemia and myocardial infarction; in addition, acetylsalicylic acid also can be used in the treatment of biliary tract roundworm disease and athlete's foot.Pharmacological actionsAcetylsalicylic acid is one of the traditional antipyretic analgesics, as well as the role of platelet aggregation. Acetylsalicylic acid in the body has the characteristics of the antithrombotic, can reduce the formation of obstructive blood clots in surrounding arteries, and inhibit release of platelet response and endogenous ADP, 5-HT, etc., therefore to inhibit second phase other than the first phase of platelet aggregation. The mechanism of action of acetylsalicylic acid is to make platelets cyclooxygenase acetylation, thus inhibiting the formation of ring peroxide, and TXA2 formation is also reduced as well. At the mean time make the platelet membrane protein acetylation, and inhibit platelet membrane enzyme, which helps to inhibit platelet function. As the cyclooxygenase is inhibited, it impacts blood vessel wall synthesized to be PGI2, the platelet TXA2 synthetic enzymes also to be inhibited; so it would impact formation of both TXA2 and PGI2 when it is large doses. Suitable for ischemic heart disease, after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, prevent transient ischemic stroke, myocardial infarction and reduce the incidence of arrhythmia.about Us:China Sinopharm International (Shanghai) Co., Ltd. is a comprehensive commercial service enterprise centering international pharmaceutical business.It is a wholly-owned subsidiary under China Sinopharm International Corporation and is affiliated to China National Pharmaceutical Group Corporation (referred to as "Sinopharm Group"), a Fortune Global 500. Founded in 1985, the company has an net asset of nearly 200 million yuan. It has complete commercial facilities and 23,000 square meters of properties including an office building and shopping malls in Shanghai's West Nanjing Road commercial area and multiple warehouses. International business are carried out based on the platforms of Sinopharm Group and Sinopharm International Pharmaceutical and aims to spread China's high-quality pharmaceutical products and services to the world.Through close cooperation with major domestic pharmaceutical companies, high-quality pharmaceutical products and overall solutions are provided to overseas customers. We are a well-known pharmaceutical enterprise in China with partners extending to more than 80 countries and regions around the world.